Has Christopher Scott, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,522 in general payments to Christopher Scott, MD across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Scott, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Scott, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Scott, MD

Dermatology · Charlottesville, VANPI 1548393234

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,460 of the $31,522 with a category attached, or 90.3%. Galderma Laboratories, L.p. accounts for 98.5% of it on its own, with 4 other manufacturers making up the rest. Among dermatology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,522in general payments, 2019–2025

Across 39 payments — averaging $808.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Galderma Laboratories, L.p.$31K
Johnson & Johnson$148
Janssen Scientific Affairs, LLC$144
AbbVie$140
Sanofi$34

What the payments were for

Speaking & faculty fees$28,46090%
Travel & lodging$1,6435%
Food & beverage$1,4195%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Galderma Laboratories, L.p.	30	$31,055
Johnson & Johnson	2	$148
Janssen Scientific Affairs, LLC	2	$144
AbbVie	4	$140
Sanofi	1	$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NEMLUVIO$11,400
Skyrizi$123

How this compares

$31,522 in reported general payments places this provider in the 90th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia →

Medicare billing

Part B allowed, 2024

$411,242

Medicare patients

1,828

Services billed

6,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
StelaraUstekinumab	18	$303,188
Dupixent PenDupilumab	62	$268,316
Taltz AutoinjectorIxekizumab	13	$87,879
Pimecrolimus	22	$14,173
Clobetasol Propionate	134	$7,117
Fluocinonide	101	$6,432
Gentamicin Sulfate	116	$6,019
Acitretin	24	$4,182
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	112	$2,850
Ketoconazole	155	$2,715
Triamcinolone Acetonide	209	$2,279
Tacrolimus	24	$2,267
Nystatin	92	$1,782
Metronidazole	30	$1,549
Fluorouracil	26	$1,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonStelara	$148	$303,18818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 396 dermatology providers in Virginia.

Other dermatology in Charlottesville

Anna MageeCharlottesville$37K
Smitha KuppalliCharlottesville$15K
Richard FlowersCharlottesville$11K
Naiem IssaVienna$2M
Saurabh SinghFairfax$1.7M
Diego DasilvaVirginia Beach$1.1M
Vishal PatelLeesburg$719K
Cyndi Torosky TommasoVirginia Beach$717K
Daniel HurdBlacksburg$545K
Jonathan SchreiberNorfolk$330K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →